Abstract:BackgroundBombesin Receptor Subtype-3 (BRS-3, Bombesin-like receptor, BB3) is an orphan G-protein coupled receptor (GPCR). Recent studies have shown that BRS-3 played a vital role in glucose regulation, insulin secretion, and energy homeostasis. Therefore, discovering more novel exogenous ligands with diverse structures for BRS-3 will be of great importance for target validation and drug development.PurposeIn this study, we aim to discover new agonists of BRS-3 from our natural compound libraries, providing a new probe to study the function of BRS-3.Study designMultiple cell-based assays and in vivo experiments were performed to identify the new ligand.MethodsBRS-3 overexpression cells were coupled with FLIPR assay, homogeneous time-resolved fluorescence (HTRF) IP-ONE assay, dynamic mass redistribution (DMR) assay, β-arrestin2 recruitment assay, and western blot to determine receptor activation and downstream signaling events. To further validate the target of BRS-3, a series of in vitro and in vivo experiences were conducted, including glucose uptake, glucose transporter type 4 (GLUT4) transportation in C2C12, and oral glucose tolerance test (OGTT) in mice.ResultsWe discovered and identified oridonin as a novel small molecule agonist of BRS-3, with a moderate affinity (EC50 of 2.236 × 10−7 M in calcium mobilization assay), specificity, and subtype selectivity. Further in vitro and in vivo tests demonstrated that oridonin exerted beneficial effects in glucose homeostasis through activating BRS-3.ConclusionsOridonin, as the discovered new ligand of BRS-3, provides a valuable tool compound to investigate BRS-3′s function, especially for target validation in type 2 diabetes and obesity. Oridonin is promising as a lead compound in the treatment of metabolic disorders. Compared to the known agonists of BRS-3, we can take advantage of the multiple reported pharmacological activities of ODN as a natural product and assess whether these pharmacological activities are regulated by BRS-3. This may facilitate the discovery of novel functions of BRS-3.

Bombesin Receptor Subtype-3 in Human Diseases

Pharmacological Characterization of a Selective Agonist for Bombesin Receptor Subtype-3

Extraintestinal Roles of Bombesin-Like Peptides and Their Receptors

Bombesin-like Peptides and Their Receptors

Bombesin-like peptides and their receptors: recent findings in pharmacology and physiology.

Extraintestinal roles of bombesin-like peptides and their receptors: lung.

Bombyx Neuropeptide G Protein–coupled Receptor A7 is the Third Cognate Receptor for Short Neuropeptide F from Silkworm

A Selective Human Bombesin Receptor Subtype-3 Peptide Agonist Mediates CREB Phosphorylation and Transactivation.

Bombesin-like Receptor 3 (brs3) Expression in Glutamatergic, but Not GABAergic, Neurons is Required for Regulation of Energy Metabolism.

Receptor-specific crosstalk between prostanoid E receptor 3 and bombesin receptor subtype 3

Recent Advances In The Biology Of Bombesin-Like Peptides And Their Receptors

Structural insights into ligand recognition, selectivity, and activation of bombesin receptor subtype-3

[Discovery of exogenous ligands for orphan receptor BRS-3 from Chinese herbs].

Structures of Human Gastrin-Releasing Peptide Receptors Bound to Antagonist and Agonist for Cancer and Itch Therapy.

Proteomics Analysis of Cellular BRS3 Receptor Activation Reveals Potential Mechanism for Signal Transduction and Cell Proliferation

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment

Bombesin/Bombesin-like Peptides and Tumor

[Protective Effect of Bombesin Receptor Subtype-3 on Human Brochial Epithelial Cells Against Injury].

A Selective Bombesin Receptor Subtype 3 Agonist Promotes Weight Loss in Diet-Induced–Obese Rats With Circadian Rhythm Change

Discovery of oridonin as a novel agonist for BRS-3

Cloning Of A Novel Protein Interacting With Brs-3 And Its Effects In Wound Repair Of Bronchial Epithelial Cells